Diseases and conditions accompanied by hypomagnesemia and hypokalemia (in complex treatment schemes): coronary heart disease; heart rhythm disorders (atrial and ventricular extrasystolic arrhythmia); vegetative vascular dystonia; myocardiopathies; violations of electrolyte metabolism ( in order to correct the level of magnesium and potassium ions) chronic fatigue syndrome.
Out of stock
active substances: magnesium salt of 2,3,4,5,6-pentahydroxycaproic acid, potassium salt of 2,3,4,5,6-pentahydroxycaproic acid
1 ml of solution contains magnesium salt of 2,3,4,5,6-pentahydroxycaproic acid in terms of 100% substance 0.0833 g, potassium salt of 2,3,4,5,6-pentahydroxycaproic acid in terms of 100% substance 0 , 0167 g;
Excipient: sodium benzoate (E 211).
Solution for injection.
The drug has metabolic, antioxidant, membrane stabilizing and antiarrhythmic effects. Metabolic activity is due to the activation of redox enzymes, increased levels of adenosine triphosphate (ATP) and creatine phosphate. This effect of the drug helps to optimize the functioning of ion pumps of cells. One of the mechanisms of the drug’s effect on cells under conditions of ischemia and hypoxia is the suppression of the intensity of the processes of free radical oxidation of proteins and lipid peroxidation. The use of the drug in conditions associated with the activation of free radical reactions is accompanied by a decrease in the permeability of cell membranes. Due to this action and the content of magnesium and potassium ions, the drug has an antiarrhythmic effect and potentiates the clinical effectiveness of antiarrhythmic drugs.
The drug is indicated as part of a comprehensive treatment for cardiac arrhythmias, including those associated with intoxication with cardiac glycosides, paroxysmal fibrillation / atrial flutter with ventricular normotachysystole, acute myocardial infarction, ventricular extrasystolic arrhythmia, arrhythmia, arrhythmia, especially in disorders of electrolyte metabolism (hypokalemia, hypomagnesemia).
The drug is used in the treatment of coronary heart disease (to reduce hypoxic and ischemic disorders of myocardial metabolism associated with coronary insufficiency). The drug is used in the treatment of myocarditis and hypokalemia caused by the use of saluretics.
Hypersensitivity to the components of the drug. Cardiogenic shock, systolic blood pressure in adults below 90 mm Hg. Art., atrioventricular block II-III degree, comatose states of unknown etiology, decompensated forms of diabetes, acute and chronic renal failure II-IV degree, Addison’s disease. The use of Ritmocor is contraindicated in hyperkalemia and hypermagnesemia.
Method of application and dosage.
Adults Ritmocor is prescribed 1-2 times a day, intravenously, by jet injection of 5-10 ml, pre-diluted in 10 ml of isotonic sodium chloride solution or 5% glucose solution. The drug is also administered intravenously: 5-20 ml of the drug is diluted in 50-400 ml of isotonic sodium chloride solution or 5% glucose solution. Usually the course of treatment is 10-14 days.
For the treatment of “pirouette” -tachycardia is administered intravenously 10-20 ml of the drug, pre-diluted in 10 ml of isotonic sodium chloride solution or 5% glucose solution, and then switch to intravenous infusion: 5-20 ml of the drug is diluted in 50-400 ml isotonic sodium chloride solution or 5% glucose solution.
Children aged 1-3 years, the drug is prescribed at the rate of 1-2 ml of solution for 1 year of life, pre-diluted in 5-10 ml of isotonic sodium chloride solution or 5% glucose solution, 1-2 times a day; children 3-6 years – at a dose of 5 ml of solution, pre-diluted in 10 ml of isotonic sodium chloride solution or 5% glucose solution, 1-2 times a day; children 6-12 years – 5-10 ml, pre-diluted in 10 ml of isotonic sodium chloride solution or 5% glucose solution, 1-2 times a day; children over 12 years of age are prescribed the drug in the same dose as adults.
The drug in this dosage form is used for children over 1 year of age.
Intravenous administration of significant doses of the drug may cause hypersensitivity to the drug, as well as manifestations of hyperkalemia and hypermagnesemia, which may be manifested by paresthesia, decreased tendon reflexes, tremors, respiratory depression. Calcium supplements are used to reduce the manifestations of hypermagnesemia.
Hypermagnesemia and hyperkalemia may be manifested by decreased tendon reflexes, tremor, respiratory depression, and arrhythmia.
Symptoms of hyperkalemia: general weakness, paresthesia, bradycardia, muscle paralysis.
Symptoms of hypermagnesemia: redness of the face, weakness, drowsiness, nausea, vomiting, diarrhea, hypotension, bradycardia, confused speech, diplopia.
The drug is well tolerated, side effects are very rare. In some cases, patients with individual hypersensitivity to the drug during its use may:
- From the gastrointestinal tract: nausea, diarrhea, vomiting, abdominal pain, discomfort or burning in the epigastric region.
- From the vessels: a feeling of heat throughout the body, dizziness and drowsiness.
- From the immune system: allergic reactions are rare, including rash, itching, hives, fever, redness of the skin. After drug withdrawal, all side effects disappear quickly. In case of allergic manifestations, desensitizing therapy is prescribed.
Store in the original package at a temperature not exceeding 25 oC.
Keep out of reach of children.